More Videos
SPECIAL REPORT
MOST SHARED
- 8 Retailers that Gain During the Holidays
- Get Paid Six Figures to Wear a T-Shirt?
- Dubai Spooks Investors But May Bring Buying Opportunity
- Finding the Holiday's Best Buys
- Tiger Woods Seriously Injured in Car Accident
- Dubai Fallout Is a Correction, Not Another Crisis: El-Erian
- Longer Lines, Fuller Carts This Black Friday
- Banks Play Down Dubai Exposure, Investors Still Wary
- The Good Entrepreneur Winner
- Global Selloff From Dubai Woes Shows Signs of Winding Down
- Black Friday at Best Buy
- Strategists on Dubai: Avoid 'Rash Moves' Now
- Longer Lines, Fuller Carts This Black Friday
- Dubai Stock Market Fear Has 'Legs': Dennis Gartman
- Obama's Emission Reduction Pledge Paints Future for Autos
- Is Super Bowl Halftime Act Too Old?
- Surprising Options Trades in TiVo Shares
- EA Sports Hopes to Pump Up Sales Through Pop-Up Locations
- 8 Retailers that Gain During the Holidays
- Tiger Woods Injured in Florida Car Accident
- Dubai Stock Selloff May Bring Buying Opportunity
- Dubai Fallout Is a Correction, Not Another Crisis: El-Erian
- Dubai's Debt Woes Signal New Era for Creditors
- Longer Lines, Fuller Carts This Black Friday
- Get Paid Six Figures to Wear a T-Shirt?
- The World's Biggest Debtor Nations
- Five Tips for Buying a Foreclosed Home
- Slideshow: Fantasy Christmas Gifts 2009
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
AP Wyeth |
We just finished back-to-back coverage of the world's largest oncology and diabetes conferences. Now we get a bit of a break before shifting our attention to Alzheimer's.
Specifically, analysts say Wyeth [WYE
Loading...
()
]and Elan[ELN
Loading...
()
] could be out with basic results on a mid-stage test for their drug by the end of this month.
Then they're expected to present the detailed data at the International Conference on Alzheimer's Disease in late July. Some analysts think if the drug shows promise it could become the biggest selling drug in history.
Bill Tanner at Leerink Swann writes in a research note to clients today that "investors should not expect to see significant treatment effects given the relatively small size of the trial and the heterogeneity of the patients population." (Dear Elanians: I'm just reporting what the man said, please do not flood my inbox with complaints about what you might see as his bearish analysis.)
Nonetheless, he believes there will probably be enough positive data for the companies to continue to move forward. Coincidentally, Brian McCarthy, a biotech analyst at Merriman Curhan Ford initiated coverage today of ELN with a Buy rating.
But he agrees with Tanner about the pending test results. "We believe a statistically significant response in Phase 2 (mid-stage clinical trial) is unlikely given the small number of patients," McCarthy writes.
He justifies his Buy rating by saying, "Positive Phase 2 Alzheimer's data could add approximately $7 in the near-term, or approximately $15 longer term if (the drug) succeeds for AD."
But buyer beware. Both analysts also say that ELN shares could be volatile in the coming weeks.
Leerink Swann may trade ELN shares. Typically, if a company doesn't have any disclosures on a stock I won't mention it. I only point them out if they exist. But since MCF is initiating coverage today I will say it has none to make.
An estimates five million Americans have Alzheimer's. That number is expected to multiply.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes